Riverview Trust Co Takes $114,000 Position in Gilead Sciences, Inc. (GILD)

Riverview Trust Co bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 1,830 shares of the biopharmaceutical company’s stock, valued at approximately $114,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Athena Capital Advisors LLC purchased a new position in Gilead Sciences during the fourth quarter valued at approximately $27,000. Advisors Preferred LLC purchased a new position in Gilead Sciences during the fourth quarter valued at approximately $31,000. Legacy Financial Advisors Inc. grew its position in Gilead Sciences by 361.3% during the fourth quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 383 shares in the last quarter. We Are One Seven LLC purchased a new position in Gilead Sciences during the fourth quarter valued at approximately $37,000. Finally, Larson Financial Group LLC purchased a new position in Gilead Sciences during the fourth quarter valued at approximately $38,000. Institutional investors and hedge funds own 78.23% of the company’s stock.

A number of brokerages recently commented on GILD. Wells Fargo & Co downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $95.00 to $68.00 in a research report on Monday, February 11th. BMO Capital Markets began coverage on shares of Gilead Sciences in a research report on Thursday. They set an “outperform” rating on the stock. Guggenheim began coverage on shares of Gilead Sciences in a research report on Monday, December 17th. They set a “buy” rating and a $86.00 price objective on the stock. Raymond James set a $90.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Tuesday, February 5th. Finally, BidaskClub raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Tuesday, December 4th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $82.56.

In related news, Director Gayle E. Wilson sold 19,068 shares of the company’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $67.08, for a total transaction of $1,279,081.44. Following the completion of the transaction, the director now directly owns 143,567 shares in the company, valued at approximately $9,630,474.36. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.16% of the stock is owned by corporate insiders.

GILD stock opened at $64.79 on Friday. The company has a quick ratio of 3.29, a current ratio of 3.38 and a debt-to-equity ratio of 1.19. Gilead Sciences, Inc. has a 12 month low of $60.32 and a 12 month high of $80.90. The company has a market capitalization of $82.69 billion, a price-to-earnings ratio of 10.53, a price-to-earnings-growth ratio of 4.08 and a beta of 1.16.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.70 by ($0.26). Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same quarter in the previous year, the firm posted $1.78 earnings per share. Gilead Sciences’s quarterly revenue was down 2.6% compared to the same quarter last year. On average, equities research analysts predict that Gilead Sciences, Inc. will post 6.23 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 28th. Investors of record on Friday, March 15th will be paid a dividend of $0.63 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.57. This represents a $2.52 annualized dividend and a yield of 3.89%. The ex-dividend date is Thursday, March 14th. Gilead Sciences’s dividend payout ratio is presently 37.07%.

ILLEGAL ACTIVITY WARNING: This story was first published by WKRB News and is the property of of WKRB News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.wkrb13.com/2019/03/15/riverview-trust-co-takes-114000-position-in-gilead-sciences-inc-gild.html.

About Gilead Sciences

Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

See Also: What are the benefits of momentum investing?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply